Pfizer and BioNTech vaccine acted on 16 different Covid-19 variants

Pfizer and BioNTech vaccine acted on 16 different Covid-19 variants

...

Scientists at Pfizer and the University of Texas tested the covid-19 vaccine, developed by Pfizer and BioNTech, on the new variant that is being seen in the UK. As a result of the data obtained, the vaccine also appeared to be effective on the new variant.

The SARS-CoV-2 Vui variant, which originated in the United Kingdom and then began to spread in many countries, was an issue of great concern to the world, especially about the vaccine. The emergence of a new variant, with ready-made vaccines in place, has also raised concerns that vaccines may be ineffective.

The welcome news came from the covid-19 vaccine, which Pfizer and BioNTech have developed together. Scientists at Pfizer and the University of Texas tested the developed vaccine on 16 different mutations, including the new variant. According to the findings, Pfizer's vaccine also has a highly effective structure for the new variant.

Pfizer vaccine tested on 16 different variants

First, let's note that this research has not yet passed the approval of the arbitrator. But since the results obtained in a positive direction will make the whole world comfortable, scientists felt the need to share this data in advance.

The studies were conducted on a group of people who were given the Pfizer vaccine. Blood samples taken were infected with SARS-CoV-2 VUI. As a result of the findings, it was revealed that the immunity developed by the vaccine in the human body is also effective on the new variant.

Phil Dormitzer, one of Pfizer's most successful vaccine scientists, said: "as part of our research, we tested 16 different covid-19 mutations on the vaccine and found that the vaccine was effective in all of them. But that means the vaccine is 17. it doesn't mean it'll have an effect on the mutant. I would say that the e484k variant, which has started to be seen in South Africa, is also extremely worrying."

Vaccines may not be effective on E484K, which is being seen in South Africa

Scientists are extremely concerned about whether the approved vaccines will have an effect on the E484K variant, which is starting to spread rapidly in South Africa. Simon Clarke, an associate professor in Cellular Microbiology at the University of Reading, has made some statements on the subject.

Clarke noted that although variants introduced in the UK and South Africa show a number of similarities, e484k has experienced a number of mutations in Virgo proteins. As you know, most Covid-19 vaccines approved are concentrated on Virgo proteins, raising concerns that the vaccine will not be effective on the e484k variant.

For more blogs; e-vaccine

Source